- Home
- FIGS vs WVE Comparison
FIGS vs WVE Comparison
Compare FIGS & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- WVE
- Stock Information
- Founded
- FIGS 2013
- WVE 2012
- Country
- FIGS United States
- WVE Singapore
- Employees
- FIGS N/A
- WVE N/A
- Industry
- FIGS Apparel
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- WVE Health Care
- Exchange
- FIGS Nasdaq
- WVE Nasdaq
- Market Cap
- FIGS 853.4M
- WVE 915.6M
- IPO Year
- FIGS 2021
- WVE 2015
- Fundamental
- Price
- FIGS $6.54
- WVE $8.40
- Analyst Decision
- FIGS Sell
- WVE Strong Buy
- Analyst Count
- FIGS 4
- WVE 14
- Target Price
- FIGS $4.88
- WVE $19.86
- AVG Volume (30 Days)
- FIGS 2.2M
- WVE 1.7M
- Earning Date
- FIGS 08-07-2025
- WVE 07-30-2025
- Dividend Yield
- FIGS N/A
- WVE N/A
- EPS Growth
- FIGS N/A
- WVE N/A
- EPS
- FIGS 0.01
- WVE N/A
- Revenue
- FIGS $561,166,000.00
- WVE $104,939,000.00
- Revenue This Year
- FIGS $0.72
- WVE N/A
- Revenue Next Year
- FIGS $2.97
- WVE $4.90
- P/E Ratio
- FIGS $898.63
- WVE N/A
- Revenue Growth
- FIGS 3.02
- WVE N/A
- 52 Week Low
- FIGS $3.57
- WVE $5.04
- 52 Week High
- FIGS $7.06
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- FIGS 72.41
- WVE 63.68
- Support Level
- FIGS $5.66
- WVE $7.69
- Resistance Level
- FIGS $6.62
- WVE $8.70
- Average True Range (ATR)
- FIGS 0.25
- WVE 0.53
- MACD
- FIGS 0.03
- WVE 0.07
- Stochastic Oscillator
- FIGS 91.11
- WVE 82.63
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.